Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$13.28
-4.3%
$15.29
$4.47
$18.60
$1.54B-0.111.08 million shs997,909 shs
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$18.15
-2.8%
$17.80
$3.81
$25.77
$1.58B1.62773,010 shs926,125 shs
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$3.58
-8.0%
$4.61
$1.80
$6.42
$404.11M0.911.54 million shs3.49 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$34.37
-4.9%
$51.85
$22.51
$60.08
$1.47B0.61419,681 shs475,689 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-4.32%-9.84%-22.43%-5.95%+205.29%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-2.84%-6.40%-0.44%+1.28%+390.54%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-7.97%-9.82%-25.88%+13.65%+100.00%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-4.92%-14.08%-37.52%-34.23%+47.13%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$13.28
-4.3%
$15.29
$4.47
$18.60
$1.54B-0.111.08 million shs997,909 shs
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$18.15
-2.8%
$17.80
$3.81
$25.77
$1.58B1.62773,010 shs926,125 shs
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$3.58
-8.0%
$4.61
$1.80
$6.42
$404.11M0.911.54 million shs3.49 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$34.37
-4.9%
$51.85
$22.51
$60.08
$1.47B0.61419,681 shs475,689 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-4.32%-9.84%-22.43%-5.95%+205.29%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-2.84%-6.40%-0.44%+1.28%+390.54%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-7.97%-9.82%-25.88%+13.65%+100.00%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-4.92%-14.08%-37.52%-34.23%+47.13%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
2.77
Moderate Buy$23.0073.19% Upside
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
2.67
Moderate Buy$32.5079.06% Upside
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3.10
Buy$16.50360.89% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.43
Hold$38.8012.89% Upside

Current Analyst Ratings Breakdown

Latest LRMR, GLUE, AMLX, and PAHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Lower Price TargetNeutral$62.00 ➝ $44.00
5/11/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
UpgradeSell (D-)Sell (D)
5/11/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Boost Price TargetOverweight$30.00 ➝ $31.00
5/8/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Reiterated RatingSell (D-)
5/8/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeBuy (B)Buy (B-)
4/28/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Boost Price TargetOutperform$19.00 ➝ $21.00
4/21/2026
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Reiterated RatingSell (D-)
4/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Initiated CoverageNeutral$62.00
4/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Initiated CoverageHold$62.00
3/25/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Reiterated RatingBuy$34.00
3/25/2026
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
UpgradeStrong-Buy
(Data available from 5/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$87.37M16.90N/AN/A$2.46 per share5.40
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$42.95M35.70N/AN/A$6.18 per share2.94
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/A$0.94 per shareN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.30B1.08$3.11 per share11.06$8.92 per share3.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$144.74M-$1.50N/AN/AN/AN/A-55.69%-50.73%N/A
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$38.63M-$1.48N/AN/AN/A-302.69%-40.99%-25.94%N/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$165.67M-$2.21N/AN/AN/AN/A-147.79%-103.07%N/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$2.3314.7510.420.556.35%37.14%8.57%6/30/2026 (Confirmed)

Latest LRMR, GLUE, AMLX, and PAHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.53-$0.31+$0.22-$0.31N/AN/A
5/7/2026Q1 2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.34-$0.37-$0.03-$0.37N/AN/A
5/7/2026Q1 2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$0.3882-$0.45-$0.0618-$0.45$10.95 million$4.21 million
5/6/2026Q3 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.72$0.76+$0.04$0.59$367.02 million$383.54 million
3/19/2026Q4 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.43-$0.73-$0.30-$0.73N/AN/A
3/17/2026Q4 2025
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$0.45-$0.55-$0.10-$0.55$17.09 million$2.78 million
3/3/2026Q4 2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.31-$0.30+$0.01-$0.30($0.05) millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/AN/AN/AN/AN/A
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/AN/AN/AN/AN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.40%N/A20.60%N/A

Latest LRMR, GLUE, AMLX, and PAHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.120.85%6/3/20266/3/20266/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
17.85
17.85
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/A
9.54
9.54
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/A
2.19
2.19
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.97
3.17
1.26

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
79.96%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
91.92%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
200111.19 million97.51 millionOptionable
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
9084.48 million79.07 millionOptionable
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
30103.88 million99.21 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.56 million20.23 millionOptionable

Recent News About These Companies

Phibro Animal Health Q3 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$13.28 -0.60 (-4.32%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$13.44 +0.17 (+1.24%)
As of 05/15/2026 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Monte Rosa Therapeutics stock logo

Monte Rosa Therapeutics NASDAQ:GLUE

$18.15 -0.53 (-2.84%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$18.16 +0.01 (+0.03%)
As of 05/15/2026 05:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Larimar Therapeutics stock logo

Larimar Therapeutics NASDAQ:LRMR

$3.58 -0.31 (-7.97%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$3.66 +0.09 (+2.37%)
As of 05/15/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$34.37 -1.78 (-4.92%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$34.33 -0.04 (-0.12%)
As of 05/15/2026 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.